aclidinium bromide 400 μg

DRUG2 trials

Sponsors

Daewoong Pharmaceutical Co. LTD., AstraZeneca

Conditions

COPDHealthy Volunteers

Phase 1

A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants

CompletedNCT03276052

AstraZenecaHealthy Volunteers

Start: 2021-10-14End: 2021-11-26Updated: 2023-12-11

Phase 3

Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT01636401

Daewoong Pharmaceutical Co. LTD.COPD

Start: 2012-08-31End: 2013-05-31Updated: 2013-08-21

Related Papers

The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants.

2023-11-271 citations

Efficacy and safety of aclidinium bromide in patients with <scp>COPD</scp>: A phase 3 randomized clinical trial in a <scp>K</scp>orean population

Respirology2015-09-1511 citations